Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, said: “The results of the PQBirch204 trial are very encouraging and they reaffirm the potential of our Pollinex platform to treat
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. The first half of fiscal 2016 has been fueled by the progress made in
Our key feature this month is a review of the UK/EU Electricity sector by Nigel Hawkins who has recently joined Hardman to cover the utilities and renewable energy market. Nigel
Panmure Gordon Analyst Dr Mike Mitchell says about Allergy Therapeutics LON:AGY “Today’s interim results confirm strong double digit constant currency revenue growth against a flat market backdrop and, even accounting
Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has given DirectorsTalk its unaudited interim results for the six months ended 31 December 2015.
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. It has an underlying profitable and cash generative business despite its lead product being
Allergy Therapeutics’ Tim Higgenbottam discusses the ATL dose ranging study in the US, safety signals and how the study has been received by the US allergists in this exclusive interview with DirectorsTalk
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its interim results for the six month period ended 31 December 2015 on Tuesday 8(th) March
Allergy Therapeutics plc (LON:AGY) the fully integrated specialty pharmaceutical company specialising in allergy vaccines, research and development director Tim Higgenbottam talks to DirectorsTalk about ATL US dose ranging study, provides
Panmure Gordon Analyst Dr Mike Mitchell said today “This morning Allergy Therapeutics has announced it has completed patient enrolment for its Phase IIb dose-finding study, G204, in the US. GrassMATAMPL
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
